19KA Stock Chart & Stats
€5.87
€2.35(31.33%)
At close: 4:00 PM EST
€5.87
€2.35(31.33%)
Day’s Range― - ―
52-Week Range€5.20 - €12.70
Previous CloseN/A
Volume0.00
Average Volume (3M)16.00
Market Cap
€600.17M
Enterprise Value€646.98M
Total Cash (Recent Filing)€178.09M
Total Debt (Recent Filing)€144.88M
Price to Earnings (P/E)3.7
Beta1.43
Next Earnings
Aug 06, 2026EPS Estimate
0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.38
Shares Outstanding78,451,890
10 Day Avg. Volume50
30 Day Avg. Volume16
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.07
Price to Sales (P/S)2.69
P/FCF Ratio4.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€12.46Price Target Upside112.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.44
Revenue Forecast (FY)€287.43M
Bulls Say, Bears Say
Bulls Say
Profitable Revenue And Cash InflectionCormedix has a durable step-change: TTM revenue near $400M with very high margins and free cash flow roughly matching net income. Strong cash conversion supports reinvestment, buybacks and balance sheet strength, improving financial flexibility versus prior loss years.
DefenCath Adoption And Durable UtilizationBroad and increasing adoption of DefenCath among large dialysis providers creates recurring, per-catheter revenue and clinical endorsement. Durable utilization and real-world evidence reduce commercialization risk, support protocol adoption, and strengthen long-term payer and provider relationships.
REZZAYO Phase III Success And Regulatory PathPositive Phase III results and an imminent sNDA materially lower clinical and regulatory risk for REZZAYO, opening a hospital prophylaxis market. A successful launch would diversify revenue beyond dialysis locks and extend hospital-facing franchise durability and addressable market size.
Bears Say
TDAPA Expiration And Reimbursement UncertaintyThe end of TDAPA add-on creates structural reimbursement uncertainty for DefenCath in H2 2026 as CMS moves to a post-TDAPA methodology. Lower interim payments or pricing transitions can materially reduce near-term revenue and margins, stressing cash flow predictability and payer negotiation leverage.
Higher Leverage After Historically Low DebtThe company’s shift from minimal leverage to materially higher debt increases financial risk if recent profitability is non-recurring. Higher interest and covenant exposure could constrain R&D or commercial spending and reduce flexibility during any revenue softness, given prior years of losses.
TPN Phase III Enrollment Delays And Push To 2028Slow enrollment and lower-than-expected event rates push the TPN Phase III timeline into 2028, delaying potential market entry and revenue diversification. Prolonged development increases cumulative R&D spend and extends reliance on core products to sustain growth and margins.
Cormedix News
19KA FAQ
What was Cormedix Inc.’s price range in the past 12 months?
Cormedix Inc. lowest stock price was €5.20 and its highest was €12.70 in the past 12 months.
What is Cormedix Inc.’s market cap?
Cormedix Inc.’s market cap is €600.17M.
When is Cormedix Inc.’s upcoming earnings report date?
Cormedix Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 34 days.
How were Cormedix Inc.’s earnings last quarter?
Cormedix Inc. released its earnings results on May 14, 2026. The company reported €0.376 earnings per share for the quarter, beating the consensus estimate of €0.3 by €0.076.
Is Cormedix Inc. overvalued?
According to Wall Street analysts Cormedix Inc.’s price is currently Undervalued.
Does Cormedix Inc. pay dividends?
Cormedix Inc. does not currently pay dividends.
What is Cormedix Inc.’s EPS estimate?
Cormedix Inc.’s EPS estimate is 0.2.
How many shares outstanding does Cormedix Inc. have?
Cormedix Inc. has 78,451,890 shares outstanding.
What happened to Cormedix Inc.’s price movement after its last earnings report?
Cormedix Inc. reported an EPS of €0.376 in its last earnings report, beating expectations of €0.3. Following the earnings report the stock price went down -1.201%.
Which hedge fund is a major shareholder of Cormedix Inc.?
Currently, no hedge funds are holding shares in DE:19KA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cormedix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€12.46 (112.25% Upside)
€12.46 (112.25% Upside)
Blogger Sentiment
Bullish
DE:19KA Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.15%
12-Months-Change
Fundamentals
Return on Equity
50.38%
Trailing 12-Months
Asset Growth
445.27%
Trailing 12-Months
Company Description
Cormedix Inc.
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
19KA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: large Q1 revenue and adjusted EBITDA beats, raised full‑year guidance, successful REZZAYO Phase III top‑line results with near‑term regulatory path, and solid cash generation. Offsetting risks include near‑term reimbursement variability from TDAPA expiry affecting H2 2026, a nonrecurring $9M revenue adjustment, mark‑to‑market charges, and a delayed TPN Phase III timeline pushing that program into 2028. On balance the positive execution, guidance increases, pipeline progress (REZZAYO) and strong balance sheet outweigh the highlighted challenges.View all DE:19KA earnings summaries19KA Stock 12 Month Forecast
Average Price Target
€12.46
▲(112.25% Upside)
Technical Analysis
Arbutus Biopharma
―
Immatics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Zenas BioPharma, Inc.
―
Options Prices
Currently, No data available
---